Salute e Benessere

Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer

Prior to Nykode, Dr Pedersen served as CSO of Symphogen (Ballerup, Denmark), where he held broad R&D responsibilities for the antibody discovery platform, lead discovery, pre-clinical as well as translational pharmacology, and advanced a number of products through IND studies and into the clinic. Following the acquisition of Symphogen by Servier, he played a critical role in the integration of the R&D team. Prior to Nykode, Dr Pedersen served as CSO of Symphogen (Ballerup,Denmark )…
PR Newswire
15/10/2024

MaineGeneral Health in the US selects Sectra's enterprise imaging SaaS to help…

Based in Augusta, MaineGeneral Health serves central Maine through a network of hospitals and outpatient facilities. In September 2024, they signed a 5-year agreement for Sectra One Cloud, and will utilize the modules for radiology and breast imaging, as well as the vendor-neutral archive (VNA). MaineGeneral Health performs approximately 200,000 exams annually. Based inAugusta, MaineGeneral Health serves centralMainethrough a network of hospitals and outpatient facilities. InSeptember...
PR Newswire
15/10/2024

Orion publishes Interim Report for January–September 2024 and holds a webcast on…

ORION CORPORATIONPRESS RELEASE15 OCTOBER 2024 at 9.00 EEST Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024 Orion will publish Interim Report for January–September 2024 on Tuesday, 29 October 2024 at approximately 12.00 noon EET. The release and related presentation material will be available on the company's website at www.orion.fi/en/investors after publishing. Webcast and conference call A webcast and a conference call for...
Nasdaq GlobeNewswire
15/10/2024

Avacta Group strengthens executive team with appointment of Michelle Morrow…

Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific OfficerLondon, Oct. 15, 2024 – Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announced the appointment of seasoned scientific leader Michelle Morrow, PhD as Chief Scientific Officer with effect from November 4, 2024. Dr. Morrow brings nearly 20…
Nasdaq GlobeNewswire
15/10/2024

ONWARD® Medical Signs Agreement with CEA for Exclusive Rights to Clinatec's…

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Company secures exclusive rights to incorporate the WIMAGINE BCI into its ARC-BCI™ SystemWIMAGINE BCI has 7-year human safety dataDeal provides opportunity for ONWARD to be first-to-market with a BCI-enabled system to restore thought-driven movement after paralysisEINDHOVEN, the Netherlands, Oct.15, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N...
Nasdaq GlobeNewswire
15/10/2024

Aidoc and Integral Diagnostics (IDX) Expand AI Partnership in Australia and New…

Aidoc's AI technology has firmly positioned IDX as the market leader in AI-driven medical imaging in Australia and New Zealand, with its aiOS™ platform automatically flagging critical pathologies, including brain aneurysms, pulmonary embolisms, stroke, and brain bleeds. Aidoc's AI technology has firmly positioned IDX as the market leader in AI-driven medical imaging inAustraliaandNew Zealand, with its aiOS™ platform automatically flagging critical pathologies, including brain aneurysms,...
PR Newswire
15/10/2024

CDK4/6 Inhibitors Market to Grow at Healthy Growth Rate by 2034 Owing to…

Key Takeaways from the CDK4/6 Inhibitors Market Report Key Takeaways from the CDK4/6 Inhibitors Market Report Discover which therapies are expected to grab the CDK4/6 inhibitors market share @ CDK4/6 Inhibitors Market Report CDK4/6 Inhibitors Market Dynamics The CDK4/6 inhibitors market has experienced significant growth in recent years, primarily driven by the increasing incidence/prevalence of cancer, particularly breast cancer. CDK4/6 inhibitors, such aspalbociclib,...
PR Newswire
14/10/2024

Information regarding the total number of voting rights and total number of…

Information regarding the total number of voting rights and totalnumberofsharesoftheCompany asofSeptember30,2024 (Article 223-16 of the General Regulations of theAutoritédesMarchésFinanciers )Market : NYSE Euronext Paris ISIN Code: FR 0010417345 DateTotalnumberofsharesTotalnumberofvotingrights 09/30/2024 96,501,526 Total gross of voting rights: 96,501,526Total net* of voting rights:...
Nasdaq GlobeNewswire
14/10/2024

Inventiva announces the availability of a prospectus in connection with its…

Daix (France), Long Island City (New York, United States), October 14, 2024– Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“ MASH ”) and other diseases with significant unmet medical needs, today announces that theAutorité des marchés financiers(the “ AMF ”) has approved a...
Nasdaq GlobeNewswire
14/10/2024

Ipsen receives its second Shingo Prize for operational excellence

Ipsen is the first pharma company in the world to receive Shingo Prizes for two sites producing treatments for patientsIpsen's first Shingo Prize was received by its production site in Signes, France in 2020, followed by the site in Dublin, Ireland todayThe Shingo Prize represents the highest standard of operational excellence in the worldPARIS, FRANCE, 14 October 2024 -Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its Dublin, Ireland production site has...
Nasdaq GlobeNewswire
14/10/2024

Illuma, Global Pioneer in HMO Research, Launches Traceability Journey in…

Scientists from illuma and Nestlé were among the first to realize the significance of HMOs in human milk more than 30 years ago. Their pioneering research led to over 75 published papers; over 100 patents relating to HMOs. The brand has carried out more than 55 HMO-related studies, including more than 30 clinical trials. Children worldwide can now benefit from multifunctional HMOs thanks to the application of these study findings, which have led to the provision of a wide range of HMO-containing…
PR Newswire
14/10/2024

Halal Empty Capsules Market Hit USD 1.55 Billion by 2029 with 5.4% CAGR |…

Browse in-depth TOC on "Halal Empty Capsules Market" Browse in-depth TOC on "Halal Empty Capsules Market" 123 - Tables40 - Figures154 - Pages The type of segment is segmented into gelatin and non-gelatin. The gelatin halal empty capsules segment dominated type segments owing to various factors such as availability of bovine gelatin, particularly from halal-certified suppliers, and their widespread use, affordability, and ease of production. The non-gelatin segment is...
PR Newswire
14/10/2024

"Maxima Grupė" Supervisory Board Dissolved

On October 14, 2024, UAB "Vilniaus Prekyba," the sole shareholder of MAXIMA GRUPĖ, UAB, decided to dissolve the company's Supervisory Board and approve a new version of the company's articles of association accordingly. The Supervisory Board, which consisted of three members from affiliated companies within the "Vilniaus Prekyba" group, functioned as a non-mandatory corporate governance body. The decision to discontinue the Supervisory Board was made to simplify the company's…
Nasdaq GlobeNewswire
14/10/2024

Tsingke Shines at Cell & Gene Therapy International 2024

At the exhibition, we had in-depth conversations with several industry decision-makers about cell and gene therapy and how Tsingke can further support scientists in making breakthroughs. Many of our customers are impressed with our self-developed synthetic materials, consumables, bioreagents, and equipment, and appreciate the quality and speed of our customized gene synthesis, oligomer synthesis, and virus packaging services. We are particularly excited about the prospects of collaboration…
PR Newswire
14/10/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 14 October 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under the...
Nasdaq GlobeNewswire
14/10/2024

Canton Fair Launches New Mobile App to Enhance Attendee Experience Ahead of…

The 136th Canton Fair, set to open on October 15, is designed to serve as a comprehensive one-stop trade platform for global buyers. It will feature an extensive range of high-quality, cost-effective, and reliable products. The fair is organized into three distinct phases, each dedicated to a specific theme: The 136th Canton Fair, set to open onOctober 15, is designed to serve as a comprehensive one-stop trade platform for global buyers. It will feature an extensive range of high-quality,...
PR Newswire
14/10/2024

Smartee Presents Mandibular Repositioning Therapy in Valencia

Local expert Prof. Vicente M. Torres Celda summarized Prof. Shen's presentation and shared his positive experiences with Smartee. Additionally, Dr. María del Carmen Pérez Cabrilla, the top user of GS in Spain, presented her GS cases and expressed her satisfaction with Smartee's services. Local expert Prof.Vicente M. Torres Celdasummarized Prof. Shen's presentation and shared his positive experiences with Smartee. Additionally, Dr. María del Carmen Pérez Cabrilla, the top user of GS in...
PR Newswire
14/10/2024

Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced…

The FDA-approved Somerset facility employs approximately 200 skilled scientists and technicians and is a Center of Excellence for advanced delivery of oral dosage forms, complementing Ardena's existing oral solid expertise. This acquisition also positions Ardena well to expand its bioanalytical services in the US to serve a growing client base driven by an ever-increasing demand for advanced drug development services. The facility's specialized technologies and analytical capabilities...
Nasdaq GlobeNewswire
14/10/2024

Buyback of Class B shares in Essity during week 41, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
14/10/2024

Chiesi Group's new Biotech Center of Excellence brings the future of medicine to…

This adaptability ensures Chiesi will remain at the forefront of medical trends, while the Center's capability will support the production of small and large batches, and both experimental and approved drugs to facilitate a seamless transition from clinical trials to commercial manufacturing. The new center will enhance Chiesi's focus areas in respiratory, special care treatments, and rare diseases, thereby strengthening its overall strategic position. This adaptability ensures Chiesi will...
PR Newswire
14/10/2024

JULIEN'S AUCTIONS ANNOUNCES "UNDER DURESS: THE BANKSY ARCHIVE OF STEVE LAZARIDES…

This extraordinary archive features some of Banksy's most famous visual artworks, including "Drill Rat," "Antenna Chimpanzee Head," "Laugh Now," "Bomb Hugger," "Love Is In The Air (aka Flower Thrower)," and "Girl With Balloon (aka Balloon Girl)," alongside rare and personal items such as Banksy's worn Puma "Turf War" sneakers, his original erotic art concept sketches, and a set of 15 burner phones used to communicate with…
PR Newswire
14/10/2024

Orion's collaboration partner Bayer submits application for third indication of…

ORION CORPORATIONINVESTOR NEWS14 OCTOBER 2024 at 11.00 EEST Orion's collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion's collaboration partner Bayer today announced the submission of an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation therapy (ADT) in patients with...
Nasdaq GlobeNewswire
14/10/2024

Modern Meadow Appoints David Williamson as CEO

NUTLEY, N.J., Oct. 14, 2024 /PRNewswire/ -- Modern Meadow, a leader in sustainable materials, has announced that David Williamson, PhD, will transition from president and chief operating officer (COO) to chief executive officer (CEO), effective October 14, 2024. Dr. Williamson has served in multiple roles within the company since 2015 and will now spearhead its next phase of growth. As CEO, Dr. Williamson will continue executing on the company's strategic growth plan to create sustainable…
PR Newswire
14/10/2024

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing…

Daix (France), Long Island City (New York, United States), October 14, 2024– Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“ MASH ”), also known as non-alcoholic steatohepatitis (“ NASH ”), and other diseases with significant unmet medical needs, today announced the filing, for the...
Nasdaq GlobeNewswire
14/10/2024
Altri  Comunicati